688247 XD宣泰医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.2743.70210.2855.1169.873
总资产报酬率 ROA (%)1.1453.2849.0734.5348.456
投入资产回报率 ROIC (%)1.2393.6079.9524.8909.309

边际利润分析
销售毛利率 (%)38.97639.41851.63155.89371.229
营业利润率 (%)15.78612.38828.12323.01440.043
息税前利润/营业总收入 (%)20.74111.59926.53419.59235.942
净利润/营业总收入 (%)17.51910.63324.96020.36737.539

收益指标分析
经营活动净收益/利润总额(%)65.92997.94689.80481.64765.801
价值变动净收益/利润总额(%)3.35921.0988.47717.22822.344
营业外收支净额/利润总额(%)18.778-3.719-1.266-4.578-1.699

偿债能力分析
流动比率 (X)10.98411.2699.46210.49410.591
速动比率 (X)10.23610.3958.4699.56210.264
资产负债率 (%)10.01010.16012.40611.11611.638
带息债务/全部投入资本 (%)-1.452-2.148-3.390-0.826-0.377
股东权益/带息债务 (%)-6,689.812-4,534.354-2,875.378-11,620.942-25,208.639
股东权益/负债合计 (%)898.967884.206706.049799.583759.286
利息保障倍数 (X)15.886-33.714-21.447-8.114-10.472

营运能力分析
应收账款周转天数 (天)67.77373.95559.61578.16776.120
存货周转天数 (天)107.308116.409136.038155.124176.402